Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS Gene Mutation”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Large-scale testing (Phase 3)Looking for participantsNCT07491445
What this trial is testing

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more
Revolution Medicines, Inc. 900
Testing effectiveness (Phase 2)Study completedNCT05340621
What this trial is testing

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Who this might be right for
RAS MutationNRAS Gene MutationMelanoma
OnKure, Inc. 36
Early research (Phase 1)Study completedNCT04742556
What this trial is testing

Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 15
Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Participants With Advanced Solid Tumors

Who this might be right for
Colorectal CancerLung CancerPancreatic Cancer
Beijing DCTY Biotech Co.,Ltd. 18
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Looking for participantsNCT05841550
What this trial is testing

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Oslo University Hospital 20
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Looking for participantsNCT06229340
What this trial is testing

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Who this might be right for
RAS MutationRas (Kras or Nras) Gene MutationColorectal Cancer Recurrent+4 more
N.N. Petrov National Medical Research Center of Oncology 20
Testing effectiveness (Phase 2)Study completedNCT01704703
What this trial is testing

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

Who this might be right for
Stage IV Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 72
Early research (Phase 1)Study completedNCT03118817
What this trial is testing

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

Who this might be right for
Solid Tumor
Hanmi Pharmaceutical Company Limited 65
Large-scale testing (Phase 3)Active Not RecruitingNCT06625320
What this trial is testing

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT06106308
What this trial is testing

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Who this might be right for
Metastatic Colorectal CancerCRCKRAS/NRAS Mutation
Cardiff Oncology 113
Not applicableStudy completedNCT02751177
What this trial is testing

Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Institut de Cancérologie de Lorraine 236
Not applicableLooking for participantsNCT04151342
What this trial is testing

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Who this might be right for
CancerMalignancies MultipleMalignant Solid Tumor+7 more
University Health Network, Toronto 5,500
Large-scale testing (Phase 3)Looking for participantsNCT06881784
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more
Revolution Medicines, Inc. 590
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Early research (Phase 1)Temporarily pausedNCT03932253
What this trial is testing

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Who this might be right for
Melanoma
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 79
Testing effectiveness (Phase 2)Looking for participantsNCT06162221
What this trial is testing

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc. 616
Load More Results